February 16, 2011 – To expand its portfolio of devices for lower extremity peripheral artery disease (PAD), Boston Scientific this week acquired two new technologies to treat chronic total occlusions (CTOs).
The first device is a re-entry catheter from S.I. Therapies Ltd., based in Israel, purchased in November. Boston will also acquire an intraluminal CTO crossing device through its acquisition of Sunnyvale, Calif.-based ReVascular Therapeutics Inc., which is expected to close this month. Worldwide launches of these devices in approved markets are planned later this year.
"Having used both devices, I am impressed with their simplicity and effectiveness," said Dierk Scheinert, M.D., Heart Center Leipzig, and professor of medicine at the University of Leipzig. "Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs."
A CTO, which represents a complete artery blockage, typically cannot be treated with standard endovascular devices such as guide wires and other catheter-based technologies. CTO devices permit endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation. By offering both a re-entry and intraluminal crossing device, Boston Scientific will be well positioned to help physicians address the challenges of treating complex peripheral lesions.
Transactional financial terms were not disclosed.
For more information: www.bostonscientific.com
April 03, 2024 
